Celecoxib and sulindac inhibit TGF-β1-induced epithelial-mesenchymal transition and suppress lung cancer migration and invasion via downregulation of sirtuin 1.
about
Prognostic and clinicopathological significance of SIRT1 expression in NSCLC: a meta-analysis.Narrower insight to SIRT1 role in cancer: A potential therapeutic target to control epithelial-mesenchymal transition in cancer cells.Oridonin inhibits migration, invasion, adhesion and TGF-β1-induced epithelial-mesenchymal transition of melanoma cells by inhibiting the activity of PI3K/Akt/GSK-3β signaling pathway.SIRT1 overexpression protects non-small cell lung cancer cells against osteopontin-induced epithelial-mesenchymal transition by suppressing NF-κB signaling.Cyclooxygenase inhibitors combined with deuterium-enriched water augment cytotoxicity in A549 lung cancer cell line via activation of apoptosis and MAPK pathways.
P2860
Celecoxib and sulindac inhibit TGF-β1-induced epithelial-mesenchymal transition and suppress lung cancer migration and invasion via downregulation of sirtuin 1.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 09 August 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Celecoxib and sulindac inhibit ...... a downregulation of sirtuin 1.
@en
Celecoxib and sulindac inhibit ...... a downregulation of sirtuin 1.
@nl
type
label
Celecoxib and sulindac inhibit ...... a downregulation of sirtuin 1.
@en
Celecoxib and sulindac inhibit ...... a downregulation of sirtuin 1.
@nl
prefLabel
Celecoxib and sulindac inhibit ...... a downregulation of sirtuin 1.
@en
Celecoxib and sulindac inhibit ...... a downregulation of sirtuin 1.
@nl
P2093
P2860
P356
P1433
P1476
Celecoxib and sulindac inhibit ...... a downregulation of sirtuin 1.
@en
P2093
Byong-Ki Cha
Byoung-Ryun Kim
Eun-Taik Jeong
Hak-Ryul Kim
Hong-Young Jun
Ki-Eun Hwang
Kwon-Ha Yoon
Kyung-Hwa Cho
Seon-Hee Oh
Young-Suk Kim
P2860
P304
57213-57227
P356
10.18632/ONCOTARGET.11127
P407
P577
2016-08-09T00:00:00Z